<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Braz J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Int Braz J Urol</journal-id><journal-id journal-id-type="publisher-id">ibju</journal-id><journal-title-group><journal-title>International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology</journal-title></journal-title-group><issn pub-type="ppub">1677-5538</issn><issn pub-type="epub">1677-6119</issn><publisher><publisher-name>Sociedade Brasileira de Urologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29064651</article-id><article-id pub-id-type="pmc">5815539</article-id><article-id pub-id-type="publisher-id">S1677-5538.IBJU.2016.0611</article-id><article-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2016.0611</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vecchioli-Scaldazza</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morosetti</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><aff id="aff1">
<label>1</label>Division of Urogynecology, ASUR, Jesi, Italy</aff><aff id="aff2">
<label>2</label>Clinical Pathology, ASUR, Jesi, Italy</aff></contrib-group><author-notes><corresp id="c1"><bold>Correspondence address:</bold> Carlo Vecchioli-Scaldazza, MD, Division of Urogynecology, ASUR, Corso Cavour 66, 62100, Macerata, Italy. E-Mail: <email>cascave@alice.it</email></corresp><fn fn-type="COI-statement"><p>
<bold>CONFLICT OF INTEREST</bold>
</p><p>None declared.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>44</volume><issue>1</issue><fpage>102</fpage><lpage>108</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>ABSTRACT</title><sec><title>Purpose</title><p>To assess effectiveness and durability of Solifenacin (SS) versus tibial nerve stimulation (PTNS) versus combination therapy (PTNS + SS) in women with overactive bladder syndrome (OAB).</p></sec><sec><title>Materials and Methods</title><p>105 women with OAB were divided randomly into three groups of 35 patients each. In group A women received SS, in group B women underwent PTNS, in group C women underwent combination of PTNS + SS. Improvements in OAB symptoms were assessed with OABSS questionnaire; patients&#x02019; quality of life was assessed with OAB-q SF questionnaire. Evaluation of effectiveness of treatments was performed with PGI-I questionnaire. OABSS and PGI-I were also assessed monthly for ten months.</p></sec><sec><title>Results</title><p>All treatments were effective on symptoms. PTNS showed a greater effectiveness than SS, but PTNS + SS was more effective than SS and PTNS. Furthermore, PTNS + SS showed a greater duration of effectiveness than PTNS and SS.</p></sec><sec><title>Conclusions</title><p>Combination of PTNS with SS showed more effectiveness and more durability than PTNS and SS alone.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Urinary Bladder</kwd><kwd>Overactive</kwd><kwd>Combined Modality Therapy</kwd><kwd>Solifenacin Succinate</kwd></kwd-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="17"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Overactive bladder syndrome (OAB) is a chronic disease characterized by urinary urgency with or without urge incontinence, frequency and nocturia (<xref rid="B1" ref-type="bibr">1</xref>) with huge economic burden and detrimental effects on the quality of life of patients (<xref rid="B2" ref-type="bibr">2</xref>). The prevalence of OAB in women increases with age and is present in approximately 30% of women over the age of 65 years (<xref rid="B3" ref-type="bibr">3</xref>) and in the general population it is estimated at 11.8% (<xref rid="B4" ref-type="bibr">4</xref>). Antimuscarinic agents represent the therapy of choice for the management of OAB, when the conservative treatment is ineffective, but although a long-lasting therapy is required to obtain better control of symptoms, a high percentage of patients discontinue the treatment after a few months (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). After failure of a single drug, most practitioners try a different pharmacological treatment and if this second option also fails, more invasive options are considered (<xref rid="B7" ref-type="bibr">7</xref>). In recent years several studies have shown that a combination of two different anticholinergic or one anticholinergic combined with the &#x003b2;3-adrenoceptor agonist Mirabegron may improve efficacy in the treatment of OAB symptoms while also reducing the side effects (<xref rid="B8" ref-type="bibr">8</xref>). Furthermore, although the available data does not allow definitive evaluation (<xref rid="B9" ref-type="bibr">9</xref>), promising results were observed with an anticholinergic combined with bladder training, electric stimulation or percutaneous tibial nerve stimulation (<xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref>). The aim of this study was to assess the efficacy and the long term durability of Solifenacin (SS) and percutaneous tibial nerve stimulation (PTNS) administered alone or in combination in the treatment of women with OAB syndrome.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>From May 2015 to December 2015, 105 consecutive women (mean age 61 years, range 41-73) with symptoms of overactive bladder (urgency, urinary frequency, with or without urge incontinence) were enrolled in this prospective, randomized, controlled study. Women were divided randomly into three groups of 35 patients each using online randomization (Graph Pad Quick Calcs software: <ext-link ext-link-type="uri" xlink:href="http://www.graphad.com/quickcalcs/randomize1">http://www.graphad.com/quickcalcs/randomize1</ext-link>) by an independent biostatistician who was unaware of treatments performed by patients and was not involved in the study. In group-A, women received Solifenacin Succinate (SS) 5mg once a day for 12 weeks. In Group-B, women underwent PTNS once a week for 30 min each for a total of 12 weeks. In Group-C, patients underwent PTNS once a week for 30 min each for a total of 8 weeks and SS 5mg on alternate days also for 8 weeks (short-low dose therapy). The treatment was performed with a 34-gauge needle electrode inserted 6-8 centimeters cephalad to the medial malleolus and slightly posterior to the tibia. The electrode was connected to the Urgent PC stimulator and a current level of 0.5 to 9mA at 20Hz was selected based on patient sensory and motor response. Patients with urinary tract infection, neurological disease, bladder lithiasis, genital prolapse higher than stage II on POP-Q system, uncontrolled narrow angle glaucoma, pelvic tumours, post void residual urine &#x02265;100mL, previously treated with radiation therapy, antimuscarinic agents, antidepressants and antianxiety agents, were excluded.</p><sec><title>Endpoints</title><p>Improvements in OAB symptoms, including day time frequency, night time frequency, urgency and urge incontinence were considered the primary efficacy end point. The impact of OAB symptoms on patient's quality of life (QoL) and the patient impression of improvement were considered the secondary end point. The primary efficacy end point was evaluated with Overactive Bladder Symptom Score (OABSS) questionnaire. It consists of 4 items related to OAB syndrome symptoms. The score of the first item (day time frequency) ranges from 0 to 2; the score of the second item (night time frequency) ranges from 0 to 3; the scores of the third and fourth items (urgency and urge incontinence respectively) range from 0 to 5. A greater score represents worsening of symptoms. The secondary end point was assessed with the Overactive Bladder questionnaire Short Form (OAB-q SF). The questionnaire consists of 6 items related to symptoms with 6 possible options ranging from &#x0201c;not at all&#x0201d; (score 1) to &#x0201c;a very great deal&#x0201d; (score 6), and a health-related quality of life scale with 13 items, with 6 response options ranging from &#x0201c;none of the time&#x0201d; (score 1) to &#x0201c;all of the time&#x0201d; (score 6). Improvement was evaluated with the Patient Global Impression of Improvement questionnaire (PGI-I). The PGI-I is a validated generic tool for assessment of the overall improvement or deterioration that patients experience following the treatment. It is a 7-point scale from &#x0201c;very much improved&#x0201d; (score 1), to &#x0201c;very much worse&#x0201d; (score 7). OABSS and PGI-I were performed before, at the end of each treatment and thereafter every month with a maximum follow-up of 10 months. OAB-q SF was performed before and after treatment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the protocol was approved by the local ethics committee. All patients signed informed consent before starting treatment. The results were assessed by a researcher blinded to treatment performed by patients.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using the MedCalc software (version 12.7.7). Data in each group was assessed by D'Agostino-Pearson test. After having checked the normal distribution, data was processed using parametric tests: paired sample t test or independent sample t test. If normality was rejected, data was processed using non-parametric tests: Wilcoxon test for paired sample and Mann-Whitney for independent sample. Data was expressed as means&#x000b1;SD. A p value &#x0003c;0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Of the 35 women initially enrolled in group A, 8 patients suspended therapy because of side effects (dry mouth, constipation); therefore, 27 patients (mean age 62 years, range 41-70) were evaluable for the study. In Group-B, only one woman suspended therapy before the end of treatment without a specific reason; therefore. 34 patients (mean age 60 years, range 45-73) were evaluable for the study. In Group-C, two women suspended therapy: one because of side effects and one without a specific reason; therefore, 33 patients (mean age 63 years, range 43-72) were evaluable. Improvements with statistically significant differences were found in all the items assessed with OABSS questionnaire in the three groups of patients: day time frequency, night time frequency, urgency and urge incontinence (<xref ref-type="table" rid="t1">Table-1</xref>). No statistical difference was found between SS versus PTNS in daily and night time micturition, whereas a significant difference was found between combination therapy versus SS (P value: 0.0167). No significant difference was found between SS versus PTNS in urgency and urge incontinence, whereas significant differences were found in those items between the group of patients who underwent combination therapy and women treated with SS and women treated with PTNS (P values: 0.0005; 0.0225 and 0.0003; 0.0015 respectively) (<xref ref-type="table" rid="t1">Table-1</xref>). Significant improvements in quality of life of patients (OAB-q SF, 6 and 13 items) were found after treatment in all groups evaluated. However, no significant difference was found between SS versus PTNS, but combination therapy showed statistically significant differences both versus SS and versus PTNS (P values: 0.0168; 0.0287 and 0.0049; 0.0561 respectively) (<xref ref-type="table" rid="t2">Table-2</xref>). Improvements in PGI-I assessed at the end of treatment were found in all groups of patients. In any case, no significance was found between SS versus PTNS, whereas combination therapy showed significant improvements both versus SS and versus PTNS (P values: 0.0017; 0.0468 respectively). Evaluation of long term durability showed persistence of improvements of SS, PTNS and combination therapy assessed with OABSS questionnaire, respectively for 0.9, 2.5 and 5.9 months; the persistence of the improvements assessed with PGI-I questionnaire was respectively 0.7, 2.1, 5.6 months (<xref ref-type="table" rid="t3">Table-3</xref>). Statistical analysis showed a significant difference respectively in PTNS versus SS, in combination therapy versus SS and versus PTNS (p values: 0.0039; &#x0003c;0.0001; 0.0009 respectively) (<xref ref-type="table" rid="t3">Table-3</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>OAB symptoms assessed with OABSS questionnaire in patients treated with Solifenacin (SS), Percutaneous Tibial Nerve Stimulation (PTNS) and Solifenacin + Percutaneous Tibial Nerve Stimulation (SS + PTNS) at the end of treatment.</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr><th align="left" rowspan="2" style="border-bottom: thin solid;background-color:#E7E7E7" valign="bottom" colspan="1">Patients N&#x000b0;</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">SS</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">PTNS</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">SS + PTNS</th></tr><tr><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">27</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">34</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">33</th></tr><tr><th align="left" rowspan="2" style="border-bottom: thin solid;background-color:#E7E7E7" valign="top" colspan="1">Age</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">62(41-70)</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">60 (45-73)</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">63 (43-72)</th></tr><tr><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" valign="middle" rowspan="1" colspan="1">OABSS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19&#x000b1;0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71&#x000b1;0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0020<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24&#x000b1;0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47&#x000b1;0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN2">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22&#x000b1;0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33&#x000b1;0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN1">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Day-time</td><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1334<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">frequency</td><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0167<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4224<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" valign="middle" colspan="1">Night-time frequency (score 0-3)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.62&#x000b1;0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">1.76&#x000b1;1.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0078<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.71&#x000b1;0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41&#x000b1;1.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0010<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.89&#x000b1;0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89&#x000b1;0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN1">*</xref>
</td></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4110<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0243<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1585<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" valign="middle" colspan="1">Urgency (score 0-5)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.29&#x000b1;0.63</td><td align="center" valign="middle" rowspan="1" colspan="1">3.43&#x000b1;1.09</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.35&#x000b1;0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">3.00&#x000b1;1.14</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN2">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.44&#x000b1;0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11&#x000b1;0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN2">**</xref>
</td></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2586<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0225<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" valign="middle" colspan="1">Urge incontinence (score 0-5)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.71&#x000b1;1.12</td><td align="center" valign="middle" rowspan="1" colspan="1">2.67&#x000b1;1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.00&#x000b1;0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">2.24&#x000b1;1.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN1">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.44&#x000b1;1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56&#x000b1;1.26</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN1">*</xref>
</td></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3742<xref ref-type="table-fn" rid="TFN3">***</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003<xref ref-type="table-fn" rid="TFN4">****</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015<xref ref-type="table-fn" rid="TFN4">****</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Wilcoxon test (paired samples);</p></fn><fn id="TFN2"><label>**</label><p>Paired samples t-test;</p></fn><fn id="TFN3"><label>***</label><p>Independent samples t-test;</p></fn><fn id="TFN4"><label>****</label><p>Mann-Whitney test (independent samples)</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Improvements assessed with Quality of Life questionnaire (6 and 13 items) (OAB-q SF 6 and 13) and Patient Global Impression of Improvement questionnaire (PGI-I) at the end of treatment.</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr><th align="left" rowspan="2" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" colspan="1"/><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">SS</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">PTNS</th><th align="center" colspan="3" style="border-bottom: thin solid;background-color:#E7E7E7" valign="middle" rowspan="1">SS + PTNS</th></tr><tr><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">before</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">after</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">p value</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" valign="middle" rowspan="1" colspan="1">OAB-q SF 6</td><td align="center" valign="middle" rowspan="1" colspan="1">3.85&#x000b1;0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">3.08&#x000b1;0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.08&#x000b1;0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">2.98&#x000b1;0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.21&#x000b1;0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">2.32&#x000b1;0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7525<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0168<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0287<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OAB-q SF 13</td><td align="center" valign="middle" rowspan="1" colspan="1">3.92&#x000b1;0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">3.16&#x000b1;0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.22&#x000b1;0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">2.96&#x000b1;0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.04&#x000b1;0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">2.27&#x000b1;0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN5">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5318<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0049<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS after</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0361<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PGI-I</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.81&#x000b1;0.96</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.41&#x000b1;0.84</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.83&#x000b1;0.76</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1997<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">SS</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0017<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" colspan="2" valign="middle" rowspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" colspan="2" valign="middle" rowspan="1">SS + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0468<xref ref-type="table-fn" rid="TFN6">**</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>*</label><p>Paired samples t-test</p></fn><fn id="TFN6"><label>**</label><p>Independent samples t-test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Persistence of improvements in months, assessed with Overactive Bladder Symptoms Score (OAB-SS) and Patient Global Impression of Improvement (PGI-I) questionnaire (follow-up of 10 months).</title></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr><th align="left" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1"/><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">SS</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1"/><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">PTNS</th><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1"/><th align="center" style="background-color:#E7E7E7" valign="middle" rowspan="1" colspan="1">SS + PTNS</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" valign="middle" rowspan="1" colspan="1">OAB-SS</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93&#x000b1;1.44</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.50&#x000b1;2.38</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">5.88&#x000b1;2.20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0039<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0009<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PGI-I</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71&#x000b1;1.13</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.10&#x000b1;1.92</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">5.63&#x000b1;2.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0017<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">vs</td><td align="center" valign="middle" rowspan="1" colspan="1">Solifenacin + PTNS</td><td align="center" valign="middle" rowspan="1" colspan="1">p</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002<xref ref-type="table-fn" rid="TFN7">*</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>*</label><p>Mann-Whitney test (independent samples)</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The study showed a significant effectiveness with improvement in all parameters evaluated with OABSS questionnaire at the end of treatment, with all the treatments performed. Combination therapy was always statistically more effective than SS and it showed a significant improvement in urgency and urge incontinence, also when compared to PTNS. Improvement in women&#x02019; quality of life was observed in all groups assessed. However, combination therapy was statistically more effective than SS and PTNS. PGI-I evaluated at the end of the treatments showed an increase in perception of improvement in all groups of women. However, combination therapy was statistically more effective compared to SS and PTNS. We considered this PTNS + SS combination therapy, a short low dose treatment. The therapy was short due to the number of PTNS treatments performed (8 treatments instead of the usual 12) and the therapy was low dose due to the administration of SS on alternate days for 8 weeks. In addition to its effectiveness, this therapeutic scheme was developed to obtain a greater adherence especially in regard to a reduction in side effects and cost.</p><p>Studies performed on combination therapy in patients with OAB showed its effectiveness without demonstrating an increase in side effects: Bolduc et al., Kosilov et al. (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B13" ref-type="bibr">13</xref>), assessed combination of two anticholinergic drugs; Abrams et al. (<xref rid="B8" ref-type="bibr">8</xref>) assessed the combination of an anticholinergic with the &#x003b2;3-adrenoceptor agonist Mirabegron. Mattiasson et al. (<xref rid="B10" ref-type="bibr">10</xref>) combined tolterodine with simplified bladder training with an improvement on voiding frequency and voided volume; Curran et al. (<xref rid="B14" ref-type="bibr">14</xref>) achieved better results by combining anticholinergic with behavioural modifications; Souto et al., Kikilyel et al. (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), assessed combination of electrical stimulations of the posterior tibial nerve versus respectively, oxybutinin and tolterodine. Amend et al. (<xref rid="B15" ref-type="bibr">15</xref>) and Abrams et al. (<xref rid="B8" ref-type="bibr">8</xref>) explained the success respectively of the combination of two anticholinergic drugs and of an anticholinergic with the &#x003b2;3-adrenoceptor agonist Mirabegron, by different receptor selectivity and by receptor interaction on different bladder wall regions. Improvements observed with the combination of PTNS with SS in this study can be explained by the blocking of muscarinic receptors that are responsible for vesical contractions caused by Solifenacine and by the effect of neuromodulation. The mechanism of bladder neuromodulation, although not completely clear, is different from that of drugs: its effect is possibly mediated through a combination of increasing cerebral endorphins, stimulation of somatic sacral and lumbar afferent fibers, and activation of efferent fibers to the striated urethral sphincter. The result of this possible mechanism is the inhibition of detrusor activity (<xref rid="B16" ref-type="bibr">16</xref>). The synergic effect of the combination therapy makes it possible to decrease the dose of each drug delivering an improved tolerability profile compared with monotherapy without compromising efficacy (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B8" ref-type="bibr">8</xref>) with a greater adherence by the patient to therapy allowing its use even in elderly patients (<xref rid="B8" ref-type="bibr">8</xref>). In this study, we assessed with particular attention the duration of effectiveness of treatments performed. SS showed a short therapeutic efficacy with a mean of improvement after discontinuation of therapy of 0.9 months. A meta-analysis conducted by Rai et al. (<xref rid="B9" ref-type="bibr">9</xref>) of 23 trials of anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome, about the permanence of the therapeutic effect of anticholinergic drugs, emphasized how &#x0201c;it is unlikely that the effects of anticholinergics persist after stopping treatment&#x0201d;. PTNS administered in monotherapy or in combination with SS showed a longer duration of effectiveness with a mean of improvement after discontinuation respectively of 2.5 and 5.8 months. A longer duration of effectiveness of PTNS was described by MacDiarmid et al. (<xref rid="B17" ref-type="bibr">17</xref>). Therefore, combination therapy showed the longest therapeutic efficacy. Souto et al. assessed the effectiveness of TENS and oxybutynin alone or in combination therapy, underlining that TENS alone or in association presented longer lasting results than oxybutynin monotherapy. The choice of therapy should be based on several factors including co-morbidities, mental status, age, education and motivation (<xref rid="B11" ref-type="bibr">11</xref>). However, in clinical practice, antimuscarinic agents are considered the first-line pharmacotherapy for OAB, although a high percentage of patients discontinue the treatment after a few months especially for poor efficacy, side effects and costs (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Therefore, the search for a therapeutic strategy that improves adherence of patients to treatment depends on its efficacy and the reduction of side effects and cost.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The combination of SS and PTNS in the treatment of OAB symptoms was an effective and well-tolerated therapy with greater improvements and longer lasting effects than single treatments. It allowed the use of lower amounts of drug with a smaller number of PTNS treatments. The low sample size of patients and the follow-up of ten months represent biases that do not allow definitive conclusions to be drawn. Further studies on a greater number of patients would be desirable to confirm this data.</p></sec></body><back><fn-group><fn fn-type="other" id="fn1"><p>Published as Ahead of Print: August 30, 2017</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>D</given-names></name><name><surname>Rosier</surname><given-names>P</given-names></name><name><surname>Ulmsten</surname><given-names>U</given-names></name><etal/></person-group><article-title>The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</article-title><source>Neurourol Urodyn</source><year>2002</year><volume>21</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11857671</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DE</given-names></name><name><surname>Milsom</surname><given-names>I</given-names></name><name><surname>Hunskaar</surname><given-names>S</given-names></name><name><surname>Reilly</surname><given-names>K</given-names></name><name><surname>Kopp</surname><given-names>Z</given-names></name><name><surname>Herschorn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</article-title><source>Eur Urol</source><year>2006</year><volume>50</volume><fpage>1306</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">17049716</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>WF</given-names></name><name><surname>Van Rooyen</surname><given-names>JB</given-names></name><name><surname>Cundiff</surname><given-names>GW</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Herzog</surname><given-names>AR</given-names></name><name><surname>Corey</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prevalence and burden of overactive bladder in the United States</article-title><source>World J Urol</source><year>2003</year><volume>20</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">12811491</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DE</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Milsom</surname><given-names>I</given-names></name><name><surname>Kopp</surname><given-names>Z</given-names></name><name><surname>Reilly</surname><given-names>K</given-names></name><collab>EPIC Study Group</collab></person-group><article-title>Understanding the elements of overactive bladder: questions raised by the EPIC study</article-title><source>BJU Int.</source><year>2008</year><volume>101</volume><fpage>1381</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">18336602</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>KE</given-names></name><name><surname>Chapple</surname><given-names>CR</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Cruz</surname><given-names>F</given-names></name><name><surname>Hashim</surname><given-names>H</given-names></name><name><surname>Michel</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence</article-title><source>Curr Opin Urol</source><year>2009</year><volume>19</volume><fpage>380</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">19448545</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YF</given-names></name><name><surname>Nichol</surname><given-names>MB</given-names></name><name><surname>Yu</surname><given-names>AP</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name></person-group><article-title>Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program</article-title><source>Value Health</source><year>2005</year><volume>8</volume><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">16091027</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolduc</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Lebel</surname><given-names>S</given-names></name><name><surname>Lamontagne</surname><given-names>P</given-names></name><name><surname>Hamel</surname><given-names>M</given-names></name></person-group><article-title>Double anticholinergic therapy for refractory overactive bladder</article-title><source>J Urol.</source><year>2009</year><volume>182</volume><issue>4 Suppl</issue><fpage>2033</fpage><lpage>2038</lpage><pub-id pub-id-type="pmid">19695628</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Kelleher</surname><given-names>C</given-names></name><name><surname>Staskin</surname><given-names>D</given-names></name><name><surname>Rechberger</surname><given-names>T</given-names></name><name><surname>Kay</surname><given-names>R</given-names></name><name><surname>Martina</surname><given-names>R</given-names></name><etal/></person-group><article-title>Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)</article-title><source>Eur Urol</source><year>2015</year><volume>67</volume><fpage>577</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">24612659</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>BP</given-names></name><name><surname>Cody</surname><given-names>JD</given-names></name><name><surname>Alhasso</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name></person-group><article-title>Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults</article-title><source>Cochrane Database Syst Rev.</source><year>2012</year><volume>12</volume><comment>12:CD003193</comment></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattiasson</surname><given-names>A</given-names></name><name><surname>Blaakaer</surname><given-names>J</given-names></name><name><surname>H&#x000f8;ye</surname><given-names>K</given-names></name><name><surname>Wein</surname><given-names>AJ</given-names></name><collab>Tolterodine Scandinavian Study Group</collab></person-group><article-title>Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder</article-title><source>BJU Int.</source><year>2003</year><volume>91</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12614251</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souto</surname><given-names>SC</given-names></name><name><surname>Reis</surname><given-names>LO</given-names></name><name><surname>Palma</surname><given-names>T</given-names></name><name><surname>Palma</surname><given-names>P</given-names></name><name><surname>Denardi</surname><given-names>F</given-names></name></person-group><article-title>Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome</article-title><source>World J Urol</source><year>2014</year><volume>32</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">23749315</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kizilyel</surname><given-names>S</given-names></name><name><surname>Karake&#x000e7;i</surname><given-names>A</given-names></name><name><surname>Ozan</surname><given-names>T</given-names></name><name><surname>&#x000dc;n&#x000fc;&#x0015f;</surname><given-names>&#x00130;</given-names></name><name><surname>Barut</surname><given-names>O</given-names></name><name><surname>Onur</surname><given-names>R</given-names></name></person-group><article-title>Role of percutaneous posterior tibial nerve stimulation either alone or combined with na anticholinergic agent in treating patients with overactive bladder</article-title><source>Turk J Urol</source><year>2015</year><volume>41</volume><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">26623150</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosilov</surname><given-names>KV</given-names></name><name><surname>Loparev</surname><given-names>SA</given-names></name><name><surname>Ivanovskaya</surname><given-names>MA</given-names></name><name><surname>Kosilova</surname><given-names>LV</given-names></name></person-group><article-title>Comparative effectiveness of combined low- and standarddose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women</article-title><source>Urol Int</source><year>2014</year><volume>93</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">25170796</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>MJ</given-names></name><name><surname>Kaefer</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Logigian</surname><given-names>E</given-names></name><name><surname>Bauer</surname><given-names>SB</given-names></name></person-group><article-title>The overactive bladder in childhood: long-term results with conservative management</article-title><source>J Urol</source><year>2000</year><volume>163</volume><fpage>574</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">10647687</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amend</surname><given-names>B</given-names></name><name><surname>Hennenlotter</surname><given-names>J</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>T</given-names></name><name><surname>Horstmann</surname><given-names>M</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Sievert</surname><given-names>KD</given-names></name></person-group><article-title>Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects</article-title><source>Eur Urol</source><year>2008</year><volume>53</volume><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">18243516</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groen</surname><given-names>J</given-names></name><name><surname>Bosch</surname><given-names>JL</given-names></name></person-group><article-title>Neuromodulation techniques in the treatment of the overactive bladder</article-title><source>BJU Int</source><year>2001</year><volume>87</volume><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">11350427</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDiarmid</surname><given-names>SA</given-names></name><name><surname>Peters</surname><given-names>KM</given-names></name><name><surname>Shobeiri</surname><given-names>SA</given-names></name><name><surname>Wooldridge</surname><given-names>LS</given-names></name><name><surname>Rovner</surname><given-names>ES</given-names></name><name><surname>Leong</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder</article-title><source>J Urol</source><year>2010</year><volume>183</volume><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">19913821</pub-id></element-citation></ref></ref-list></back></article>